Days after Glenmark Pharmaceuticals launched its anti-viral drug to treat coronavirus patients, the company's shares surged 40 per cent to Rs 572.7 on Monday in the intra-day trade on the BSE.

Glenmark's shares rise up to 40% following launch of potential coronavirus drug

favipiravir-glenmark

Favipiravir Glenmark, News on Favipiravir Glenmark, stories on Favipiravir Glenmark, articles on Favipiravir Glenmark, Favipiravir Glenmark stories at Wion, Favipiravir Glenmark news, Favipiravir Glenmark latest news

favipiravir glenmark

Glenmark's shares rise up to 40% following launch of potential coronavirus drug